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Abstract
Tyrosine kinase 2 (TYK2) is a member of the Janus kinase (JAK) family and is involved in cytokine signalling. In vitro analyses
suggest that TYK2 also has kinase-independent, i.e., non-canonical, functions. We have generated gene-targeted mice
harbouring a mutation in the ATP-binding pocket of the kinase domain. The Tyk2 kinase-inactive (Tyk2
K923E) mice are viable
and show no gross abnormalities. We show that kinase-active TYK2 is required for full-fledged type I interferon- (IFN)
induced activation of the transcription factors STAT1-4 and for the in vivo antiviral defence against viruses primarily
controlled through type I IFN actions. In addition, TYK2 kinase activity was found to be required for the protein’s stability. An
inhibitory function was only observed upon over-expression of TYK2
K923E in vitro. Tyk2
K923E mice represent the first model
for studying the kinase-independent function of a JAK in vivo and for assessing the consequences of side effects of JAK
inhibitors.
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Introduction
Tyrosine kinase 2 (TYK2) belongs to the Janus kinase (JAK)
family of non-receptor tyrosine kinases that, in mammals,
additionally comprises JAK1-3 [1,2]. JAKs associate with a variety
of cytokine and growth factor receptors and upon ligand binding
undergo auto- and/or cross-phosphorylation. Activated JAKs
phosphorylate receptor chains and members of the signal
transducer and activator of transcription (STAT) family. Phos-
phorylated STATs are homo- or heterodimers and translocate to
the nucleus to initiate transcription. This is referred to as the linear
– i.e. canonical – JAK-STAT signalling pathway [3]. Functionally,
TYK2 was first identified as crucially contributing to type I
interferon (IFNa/b) responses [4]. Murine and human cells
deficient for TYK2 were instrumental in defining additional
biological functions of TYK2 in signalling for a selection of
cytokines [5]. Three groups have used gene targeting to create
mouse models for Tyk2 deficiency [6,7,8] and an additional model
is provided by the naturally occurring Tyk2 mutant strain B10.Q-
H
2q/Sgj (B10.Q/J) [9]. A human fibrosarcoma cell line lacking
TYK2 was used in the majority of early studies on the protein’s
functions [4,10]. Recently, a patient with TYK2 deficiency has
been reported and initial studies confirm most findings from
mutant mice and human cell lines, although they also pinpoint
some differences between species [11].
Type I IFNs comprise several IFNa subtypes and one IFNb and
signal through IFNAR1 associated with TYK2 and IFNAR2/
JAK1. IFNAR engagement primarily activates STAT1/2 hetero-
dimers, which activate transcription together with IFN regulatory
factor (IRF) 9. Cell type-specific type I IFN responses are mediated
through additional activation of STAT3-6 [12,13]. In addition to
this canonical JAK-STAT pathway, alternative transcription
factors are activated and there is cross-talk with other pathways
– i.e. non-canonical signalling [14,15]. TYK2 deficiency in the
human fibrosarcoma cell line [4] and in T cells of a patient
carrying a homozygous mutation of the TYK2 gene [11] leads to
unresponsiveness to IFNa. By comparison, Tyk2-deficient mice
have a reduced IFNa/b response. This has been attributed to a
strong reduction of IFNAR1 surface levels in human TYK2-
deficient cells, while mutant murine cells express unchanged
IFNAR1 levels [5].
TYK2 shares with the other JAKs the conserved structure of
seven JAK homology (JH) domains, wherein the C-terminal JH1
and JH2 encode the kinase and pseudokinase domain, respectively,
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domains [1,16]. The JH1 domain shows all the characteristics of
a classical tyrosine kinase [17,18], including conserved activation
loop tyrosines and the ATP-binding residues. The mutation of
either of these residues results in an impairment of catalytic activity
[19,20]. JH2 exerts regulatory functions with specific point
mutations either abolishing or increasing the catalytic activity of
TYK2 [21,22,23,24]. JAKs may also actuate biological functions
independently of their catalytic activity. To date, the best described
effects relate to the in vitro stabilization of receptors and seem to be
restricted to distinct receptor/JAK combinations. TYK2 stabilizes
human IFNAR1 independently of its kinase domain [25,26], and
similar functions are described for other JAKs [27,28]. In addition,
kinase-independent functions of JAKs have been reported in the
context of signal pathway crosstalk and mitochondrial functions
[29,30,31]. Hence, the description of the full spectrum of JAK
activities requires a consideration not only of kinase-dependent
functions but also of non-canonical functions.
To dissect the canonical and non-canonical functions of TYK2
in vivo we gene-targeted the Tyk2 locus, introducing a point
mutation into the exon encoding the ATP-binding pocket. The
resulting Tyk2 kinase-inactive (Tyk2
K923E) mice appear phenotyp-
ically normal in comparison to wild-type (WT) littermates.
Analysis of the IFNa/b responses in vitro and in vivo revealed that
(i) TYK2 kinase activity is essential for unperturbed signalling and
(ii) the kinase-inactive protein exerts no inhibitory effects.
Unexpectedly, we found a dependence of TYK2 protein stability
on the JH1-mediated kinase activity. This might be of particular
interest when considering the use of pharmacological TYK2
inhibitors in future clinical settings.
Results
Generation of Tyk2 Kinase-inactive Mice
A kinase-inactive murine TYK2 analogous to the kinase-
inactive human TYK2 protein [19] was generated by exchanging
the conserved lysine (K923, NCBI GenBank: AF173032.1) in the
kinase domain, which is essential for the catalytic activity, to
glutamic acid (E) (Fig. 1B). The murine TYK2
K923E showed no
enzymatic activity in an in vitro kinase assay (Fig. 1A), confirming
data from human [19,20] and murine [29] TYK2.
The gene-targeting vector for the generation of kinase-inactive
Tyk2 mice is depicted in Fig. 1B. Targeted ES cells were generated
as described [32] and successful targeting of the Tyk2 locus was
verified by Southern Blot and PCR (Figs. 1C and D). Finally, the
point mutations and vector integration sites were verified by DNA
sequencing (data not shown). Six germline competent chimeras
were obtained and gene-targeted line #29 was bred to Tg(CMV-
Cre) mice [33] to remove the neomycin resistance cassette.
Intercrossing of F1 generation mice demonstrated that
B6N;129P2-Tyk2
tm3(K923E)Biat (Tyk2
K923E) mice were born at a
normal Mendelian ratio, showed no apparent abnormalities and
were fertile. The Tyk2
K923E line was backcrossed to C57BL/6N
background by speed congenics [34].
The Stability of the TYK2 Protein Partially Depends on its
Tyrosine Kinase Activity
Immunoprecipitation followed by Western Blot was performed
with lysates from WT and Tyk
K923E whole cells and organs to
analyse TYK2 levels. A clear reduction of TYK2
K923E compared
to WT protein levels was detected in all primary cells (bone
marrow macrophages (BMMWs) and T cells, Fig. 2A upper and
middle panel; and murine embryonic fibroblasts (MEFs), data not
shown) and organ extracts (liver, lung and spleen, Fig. 2A lower
panel) we examined. Although immunoprecipitation and Western
Blot technology are only semi-quantitative, it is noticeable that the
WT TYK2 levels vary between organs, decreasing from spleen to
lung and liver (Fig. 2A, lower panel), while JAK1 is more evenly
expressed.
To eliminate the possibility that TYK2
K923E activity directly or
indirectly influences its own expression and to verify the
transcriptional integrity of the targeted locus, we analysed Tyk2
mRNA by RT-qPCR. No significant differences in mRNA
expression in BMMWs isolated from WT or Tyk2
K923E mice were
detected (Fig. 2B). Similar results were obtained by analysing T
cells and extracts from spleen, liver and lung (data not shown).
We next monitored the degradation of the mutated TYK2
protein. The ubiquitin-proteasome and the autophagy-lysosome
systems are two major pathways triggering the degradation of
proteins in mammalian cells [35,36]. The pathways can be
inhibited by treating cells with MG-132 or 3-methyladenine (3-
MA), respectively. We tested the stability of TYK2
K923E in
BMMWs in the presence of MG-132. As a positive control we used
heme oxigenase-1 (HO-1), which is stabilized when the protea-
some pathway is blocked [37]. WT TYK2 levels remained
unperturbed upon MG-132 treatment, while TYK2
K923E protein
decreased after 2 h and was no longer detectable after 6 h of
proteasome inhibition (Fig. 2C upper panel). In contrast,
treatment of BMMWs with 3-MA for 11 h nearly restored
TYK2
K923E levels to the level of WT TYK2 (Fig. 2C middle
panel). The enhanced TYK2
K923E degradation upon proteosomal
inhibition can be explained by enhanced targeting to the
autophagy-lysosomal machinery, as has been reported for other
proteins [38]. In addition, we used bafilomycin A1 to block
lysosomal acidification [39]. Again, treatment substantially
increased TYK2
K923E protein level (Fig. 2C, lower panel). As
positive control LC3-I and -II (microtubule-associated protein 1
light chain 3) accumulation was used [40]. To test whether the
decreased TYK2
K923E stability is due to inactivation of the kinase
rather than being a consequence of the point mutation that had
been introduced, we treated WT cells with a panJAK inhibitor at
different concentrations and time periods (Fig. 2D, upper and
lower panel). A clear reduction of TYK2 protein was observed,
although JAK2 levels remained stable (Fig. 2D). In conjunction,
our results suggest that TYK2’s kinase activity is required to
prevent its lysosomal-mediated degradation.
Tyk2
K923E and Tyk2
2/2 Innate and Adaptive Immune Cells
Show Similar Impairment of IFNb-induced STAT
Activation
Full activity of cytokine receptors binding TYK2 always
depends on the binding of at least one additional JAK, so binding
of TYK2 alone is insufficient to transduce signals. For example,
JAK1 is the decisive upstream transphosphorylating kinase for
TYK2 at the IFNAR or the gp130-utilising receptors [19,41]. We
have previously shown that JAK1 is phosphorylated on tyrosine
residues upon treatment with IFNb in the absence of TYK2,
although the level of phosphorylation is reduced compared to WT
[6]. We now assessed the phosphorylation state of JAK1 and
TYK2 associated with IFNAR in IFNb-treated WT and gene-
targeted BMMWs. JAK1 activation was detectable in the presence
of kinase-inactive TYK2 and in the absence of TYK2 (Fig. 3A, left
panel). Consistent with its reported function as a subordinate
kinase, TYK2
K923E shows IFNb-induced tyrosine phosphorylation
(Fig. 3A, right panel). In addition to confirming the JAK1/TYK2
kinase hierarchy at the IFNAR complex, these findings suggest
that the receptor architecture is intact in cells expressing kinase-
inactive TYK2.
TYK2 Kinase Inactive Mouse
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activation upon type I IFN stimulus in BMMWs [6]. The ability of
BMMWs collected from Tyk2-deficient and kinase-inactive mice to
activate STAT1-3 in response to IFNs was compared. In
agreement with previous findings [6,42] the levels of STAT1 and
2 proteins were decreased in Tyk2
2/2 BMMWs; we found similar
results in Tyk2
K923E cells (Figs. 3B and C). In contrast, the levels of
STAT3 protein were unaffected in Tyk2-mutant cells (Fig. 3D).
Treatment of BMMWs with IFNb caused reduced tyrosine
phosphorylation of the STAT1 isoforms, STAT2 and STAT3
(Figs. 3B–D); the extent of reduction was similar in Tyk2
2/2 and
Tyk2
K923E cells. The level of IFNa-induced STAT1-3 phosphor-
ylation was just above detection limit and no gross differences
between genotypes were observable. Treatment with IFNc resulted
in a slight reduction between WT and the two mutant genotypes in
levels of activated STAT1 but not STAT3 (Figs. 3B and D). To
investigate potential dose-dependent effects, we treated BMMWs
with varying amounts of IFNb. There was a clearly dose-dependent
increase of tyrosine-phosphorylated STAT1 in WT and Tyk2-
mutated cells, although the mutant BMMWs do not reach the levels
of STAT1 activation exhibited by WT cells at least within the dose
range tested (Fig. 3E).
In addition to STAT1 and 2, NK cells and T cells directly
activate STAT4 upon IFNa/b treatment [13]. Analysis of IFNb-
treated NK cells revealed that lack of TYK2 and expression of
mutant TYK2 equally impaired the phosphorylation of STAT1
and STAT4 (Figs. 3F and H). This was observed for doses up to
500 U/ml (Fig. 3F) and during the time course tested (Fig. 3H).
Similar results were obtained with IFNa (Fig. 3G) and with ConA-
activated splenocytes and T cells stimulated with IFNb (data not
shown). Note that levels of STAT4 do not differ between
genotypes.
This experiment proves that upon IFNAR engagement (i) JAK1
is autophosphorylated in Tyk2
2/2 as well as in Tyk2
K923E cells and
(ii) JAK1 transphosphorylates TYK2
K923E. Kinase-inactive TYK2
cannot compensate for the loss of TYK2 protein in the activation
of STAT1-4 by type I IFN in innate and adaptive immune cells,
while – at least at the levels detected – kinase-inactive TYK2
expressed ex vivo does not block JAK1 activity.
IFN-induced Transcriptional Activation of Target Genes
does not Differ between Tyk2
2/2 and Tyk2
K923E Cells
We previously reported that in macrophages many IFN
response genes are less expressed at the basal, i.e. uninduced,
state in the absence of TYK2. Upon inflammatory or viral
stimulus the IFN response genes become less dependent on
TYK2 [42,43]. We analysed the expression of genes induced
predominantly by IFN type I (Ifit1, Oas1a, Ifi204, Irf7) or by both
IFN type I and II (Tap1, Cxcl10, Socs1, Irgm1). By means of RT-
qPCR we monitored the levels of gene expression in WT,
Tyk2
2/2 and Tyk2
K923E BMMWs either untreated or treated with
IFNa, b or c. In accordance with our previous observations, the
response genes showed differential TYK2 dependency. We could
divide the genes into three groups depending on their response to
IFN treatment: (i) Oas1a and Ifit1 were Tyk2-independent
(Fig. 4A); (ii) Cxcl10, Socs1 and Irgm1 were Tyk2-dependent upon
induction by IFN (Fig. 4B and data not shown); and (iii) Tap1,
Irf7 and Ifi204 were Tyk2-dependent in the uninduced and
induced states (Fig. 4C and data not shown). As anticipated from
their similar STAT1-3 phosphorylation patterns, comparison of
uninduced mRNA expression levels and IFNa/b inducibility
showed no differences between Tyk2
K923E and Tyk2
2/2 cells
(Fig. 4A–C). Analysing the induction of Cxcl10 and Irf7 with
IFNb at different doses also revealed no differences between the
mutant genotypes (Fig. 4D). Among the six genes analysed, only
two (Cxcl10 and Socs1, Fig. 4B) show significant dependence on
kinase-active Tyk2 upon IFNb (p,0.05), but not in response to
IFNa. However a similar tendency (p,0.1) was seen for IFNa.
Tyk2
K923E and Tyk2
2/2 Mice Show Increased Susceptibility
to Viral Infections
To determine the immuno-competence of kinase-inactive Tyk2
mice we infected mice with VSV and EMCV and monitored
their survival. These viruses were chosen because they are
predominantly cleared from the host through type I IFN-
mediated mechanisms [44,45]. We previously reported that upon
i.v. administration WT and Tyk2
2/2 mice resist challenge by
VSV [6], so we elected to use intranasal (i.n.) instillation, which
is known to increase the susceptibility to lethal disease by 3-4-fold
[46]. At a dose of 10
5 pfu/mouse, .60% of the WT mice
survived the challenge while none of the Tyk2
2/2 and Tyk2
K923E
mice survived for longer than d7 (Fig. 5A). Tyk2-mutant mouse
strains were then infected i.p. with 50 pfu EMCV and survival
was monitored. WT mice had a survival rate of 40%, whereas
Tyk2
2/2 mice showed 100% mortality and Tyk2
K923E mice
showed a level of mortality that was slightly reduced, although
the difference was not statistically significant (Fig. 5B). Thus
kinase-active TYK2 is required for the antiviral responses against
VSV and EMCV in vivo.
Discussion
To dissect the enzymatic and putative non-enzymatic functions
of TYK2 in vivo we generated knockin mice carrying Tyk2 alleles
(Tyk2
K923E) with a point mutation that inactivates the ATP-binding
pocket of the kinase domain (Fig. 1). Consistent with the findings
from mice lacking the TYK2 protein [6,7,8,9], loss of the kinase
activity does not prevent mice from developing and reproducing
normally. In an analogous approach, it was shown that JAK2-
Figure 1. TYK2
K923E is enzymatically inactive and generation of Tyk2
K923E mice. A. The in vitro kinase activity assay was performed in a TYK2-
deficient cell line transiently transfected with plasmids encoding GFP, wild-type TYK2 or kinase-inactive TYK2
K923E. TYK2 and TYK2
K923E proteins were
immunoprecipitated from cell extracts and subjected to an in vitro kinase assay using GST-IFNARcyt as an exogenous substrate (left panel). TYK2 was
immunoprecipitated from whole cell extracts and Western Blot analysis performed to detect phosphorylated TYK2 (pTyk2, upper right panel) or TYK2
protein (lower right panel). B. Scheme of the murine Tyk2 locus from exons 9-24 (black boxes). The point mutations introduced in exon 20 resulting in
the amino acid exchange K.E and the introduction of the BspTI restriction endonuclease site are depicted. The neomycin resistance cassette (neo
r,
white box) flanked by loxP sites (black triangles) was inserted into the intron sequence between exons 21 and 22. The lower scheme shows the
targeted locus with the restriction sites important for Southern blot analysis. Note that after germline transmission the neo
r cassette was excised to
leave a single loxP site in the mutated allele. C. Southern blot analysis using a non-radioactively labelled 471 bp neo
r probe verified correct targeting
and lack of heterologous integration in the ES cell clone 1, whereas two other clones (2 and 3) were not correctly targeted. D. DNA from WT (+/+),
heterozygous (+/m) or homozygous Tyk2
K923E (m/m) mouse tails was used to amplify a 710 bp fragment with primers surrounding exon 20. The
amplicons were digested with BspTI resulting in a 498 bp and a 212 bp fragment only in the Tyk2
K923E alleles. E. Conventional genotyping of mouse
tails results in a 678 bp fragment corresponding to the WT and a 778 bp fragment specific for Tyk2
K923E.
doi:10.1371/journal.pone.0039141.g001
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K923E protein level is reduced and TYK2 differs organ-specifically. A. WT, Tyk2
2/2 and Tyk2
K923E mice were used to prepare
whole cell extracts from BMMWs, T cells and various organs (as indicated). Levels of expression of TYK2 and JAK1 were determined by
immunoprecipitation and Western blot analysis. NFkB-p65 was used as input control. TYK2
K923E protein levels were quantified using ImageJ software
for Mac OS X (open source, http://rsb.info.nih.gov/ij/index.html) and were between 13% and 30% in BMMWs and approximately 58% in T cells
compared to WT. B. Total RNA was isolated from WT and Tyk2
K923E BMMWs and cDNA was used to analyse Tyk2 mRNA expression normalized to the
housekeeping gene Ube2D2. Results from 4 independent experiments are shown (n=6 per genotype). C. BMMWs were treated with the proteasomal
inhibitor MG-132 (50 mM), the autophagy-lysosome inhibitor 3-MA (10 mM) or the lysosome-acidification inhibitor bafilomycin A1 (80 nM) for the
indicated period of time (upper panel), for 11 h (middle panel) or 48 h (lower panel). Whole cell extracts were used to determine TYK2 and JAK1
TYK2 Kinase Inactive Mouse
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i.e. embryonal lethality [47].
Tyk2
2/2 and Tyk2
K923E mice show no significant differences in
activation of STAT1-4 induced by type I IFN, in transcriptional
activation of IFN target genes or in survival upon viral infection
(Figs. 3–5). This indicates that, with regard to type I IFN
signalling, TYK2
K923E is not capable of complementing TYK2
deficiency nor does it act in an inhibitory manner. TYK2 kinase
activity has been shown to be indispensable for IFNb-induced
apoptosis and for mitochondrial respiration in murine pro-B cells
[29] and for IFNb-induced gene expression and STAT3 activation
in human fibroblasts [30,48,49]. The lack of biological activity in
the type I IFN system is unlikely to result from limited availability
of TYK2
K923E (see below) because a block of protein degradation
and consequent increase of TYK2
K923E levels does not alter cells’
responsiveness to type I IFN (data not shown) and because
inhibitory effects are only observed upon massive over-expression
of TYK2
K923E in Tyk2
2/2 MEFs (C. Gausterer unpublished). In
contrast, experiments with Jak2 kinase-inactive mice revealed a
mild dominant-negative phenotype of the mutated protein in vivo,
while over-expression in vitro had an inhibitory effect [47].
Substitution of K923 into E leads to lower levels of TYK2
protein in various cells and organs. The drop is not caused by
impaired transcriptional activity of the Tyk2
K923E locus, as
TYK2
K923E becomes more stable when the autophagosomal
degradation pathway is blocked (Fig. 2). Lack of stability (or
immunogenicity) in lymphocytes was previously observed in
B10.Q/J mice carrying the TYK2
E775K mutation in the
pseudokinase domain and this change was not reversed upon
treatment with the proteasomal inhibitor MG-132 [9]. This
finding supports our notion that mutated TYK2 is not exposed to
proteasomal degradation. In contrast, Jak2 kinase-inactive MEFs
showed unperturbed stability of JAK2 [47]. Decreased TYK2
protein stability also seems to be a consequence of treating cells
with JAK kinase inhibitors (see Fig. 2). We therefore propose
including the assessment of JAK protein stability in future studies
relating to the development or efficacy evaluation of JAK kinase
inhibitors.
To date, JAKs and/or STATs have only been reported to be
degraded by the proteasomal pathway under the control of SOCS
(suppressors of cytokine signalling) [50,51]. TYK2 is known to
interact with SOCS1 [52,53,54,55], although its proteasomal
degradation per se has been studied only recently in the context of a
viral IFN response evasion mechanism [56]. At the IFNAR,
TYK2 is only destabilised when it is phosphorylated on binding to
a ligand [54]. This suggests that SOCS-mediated proteasomal
degradation may be specific for TYK2 activated by cytokines.
Ligand-induced activation of TYK2 is governed by JAK1-
mediated cross-phosphorylation of conserved tyrosine residues
within the activation loop of the kinase domain. Additional
tyrosines with putative regulatory functions that are potentially
auto-phosphorylated have been identified by phosphoproteome
mapping [5]. Although the lack of specific antibodies makes it
impossible to test the idea, it is tempting to speculate that
autophagosomal degradation of TYK2 is the cellular mechanism
for regulating TYK2 levels under unstimulated physiological
conditions, with auto-phosphorylation as one of the underlying
regulatory mechanisms.
Interestingly, the basal TYK2 protein levels in WT cells differ
considerably between organs and tissues (Fig. 2). TYK2 is widely
reported to be ubiquitously expressed [2,5]. The gene portal
system BioGPS (http://biogps.org) lists some differences in Tyk2
mRNA expression, with highest basal levels in lymphoid organs
and cells. Nevertheless, reports of cell-specific variations in TYK2
amounts and their biological consequences are sparse. One paper
correlated cell-type differences in available amounts of type I IFN
signalling components, including TYK2, with intensity of response
upon paracrine cytokine stimulation [57]. The authors suggested
that cells are armed with elevated levels of signal transduction
components to restrict the spread of pathogens. It remains to be
established whether the disposable protein level is a molecular
mechanism by which cells utilise TYK2 in different signalling
cascades and organ-specific textures.
In conclusion, we report that kinase-inactive TYK2 cannot
compensate for loss of TYK2 in type I IFN-mediated responses in
vitro and in vivo and that inhibition of TYK2 kinase activity in vivo
does not exacerbate the phenotype of loss of TYK2 with respect to
virus susceptibility. Our future work will address the requirement
for TYK2 kinase function in a tissue-restricted context and in
cytokine response networks other than type I IFNs. To date,
kinase-independent functions of TYK2 have only been described
in human cells, in which catalytic activity is not required for
IFNAR1 cell-surface anchoring and activation of PI3 kinase
[25,30], and in murine cells, in which kinase-inactive TYK2 is
sufficient to enable basal mitochondrial respiration [29]. We show
that inactivation of TYK2’s enzymatic activity by mutation or
pharmaceutical intervention within the ATP binding pocket
interferes with the protein’s stability. The translational research
attempting to develop TYK2 kinase inhibitors [58,59] should
consider this potential side effect, which may be harnessed in
future clinical applications. Tyk2
K923E mice provide the first in vivo
model for testing off-target effects of JAK inhibitors.
Materials and Methods
Ethics Statement
Mice were housed under specific pathogen-free conditions
according to FELASA guidelines. All animal experiments were
discussed and approved by the Ethics and Animal Welfare
Committee of the University of Veterinary Medicine Vienna and
conform the National Authority (Austrian Federal Ministry for
Science and Research according to 18ff of Law of Animal Science
and Experiments (Tierversuchsgesetz – TVG; refs. BMBWK-
68.205/0240-BrGT/2005 and BMWF 68.205/0233-II/10b/
2009).
Tyk2
K923E Gene Constructs
The expression plasmid pEFmTyk2 was cloned by inserting the
murine Tyk2 cDNA (NCBI GenBank: AF173032.1) into the
polylinker of pEF-Zeo [60], controlling Tyk2 expression by the
elongation factor 1a promoter. For the single nucleotide exchanges
in the Tyk2 cDNA the PCR mutagenesis strategy described
previously [19] was used. The nucleotide sequences of the primers
were as follows (the mutated codons are underlined): mut-f 59-
GAGATGGTGGCCGTGGAGGCCCTTAAG-
GAAGGGTGCG-39; mut-r 59-CGCACCCTTCCT-
TAAGGGCCTCCACGGCCACCATCTC-39; external-f 59-
expression levels by immunoprecipitation and Western blot analysis. As a control, a Western blot for HO-1 was performed. D. From day 5 after
isolation of WT BMMWs, cells were treated with JAK inhibitor I (panJAK inhibitor; 15 nM upper panel and 300 nM lower panel) for the indicated period
of time. TYK2 and JAK2 expression levels were analysed as described in (A and C); NFkB-p65 was used as input control.
doi:10.1371/journal.pone.0039141.g002
TYK2 Kinase Inactive Mouse
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r5 9-TCTGGATCCTGGAGCCCTG-39. The resulting plasmid
containing the mutated Tyk2 cDNA was termed pEFmTyk2
K923E.
To clone the gene-targeting vector the pKO-V920-Scrambler
plasmid was used (Stratagene, La Jolla, CA; NCBI GeneBank:
AF087567). The positive selection marker neomycin flanked by
loxP sites was excised from the pKSloxPNT plasmid [61] (kindly
provided by Alexandra L. Joyner of the New York University
Medical Center, NY USA). The construct contained the long
homologous arm with 8,039 bp (spanning exons 10-21, NCBI
GeneBank: AC163637.4), the 2 kb neomycin cassette flanked by
loxP sites and the short homologous arm with 1,254 bp (spanning
exons 22 and 23) (Fig. 1B). Nucleotide exchanges into exon 20 of
the murine Tyk2 locus were introduced by site directed mutagen-
esis. A157820 was mutated to G157820 resulting in the amino
acid exchange K.E in the ATP binding pocket of TYK2 (see
above). An additional mutation from G21925 to T21925 was
introduced, which did not affect the amino acid sequence but
created an additional restriction site for the endonuclease BspTI.
Purification of Recombinant GST-IFNARcyt Fusion Protein
E.coli (XL1 blue) transformed with the pGEX-GSTIFNAR2cyt
expression vector (kindly provided by Sandra Pellegrini, Institute
Pasteur Paris, France) was grown in LB medium supplemented
with 100 mg/ml ampicillin to an OD600 nm of 0.6 to 0.8. Isopropyl
b-D-1-thiogalactopyranoside (IPTG, 0.1 mM) was added and
incubation continued for a further 1 hour with shaking at 30uC
before cells were harvested by centrifugation. Bacterial pellets were
resuspended in ice-cold PBS supplemented with 1% (v/v) Triton
X-100, 1 mg/ml lysozyme and 1 mM PMSF. If not indicated
otherwise all reagents were from ROTH (Karlsruhe Germany).
The bacterial suspensions were frozen in liquid nitrogen and
thawed on ice (3 cycles). Suspensions were sonicated four times for
30 seconds at 50% continuous power using the HD70 Sonopuls-
ultrasonic-homogenizer (Bandelin Electronic GmbH & Co KG,
Berlin Germany). Bacterial debris was pelleted (14000 g, 10
minutes at 4uC) and the supernatants used for affinity purification.
A pre-packed column of glutathione sepharose 4B (GE Health-
care, Little Chalfont UK) was washed with 20 ml cold (4uC) PBS.
The column’s gel bed was equilibrated with 6 ml PBS supple-
mented with 1% Triton X-100. Bacterial lysates were clarified by
centrifugation and filtering (0.45 mm pore size) and applied to the
column. The column was washed twice with 10 ml PBS, then
bound material was eluted with 10 ml elution buffer (5 mM
glutathione in 50 mM Tris-HCl pH 8.0). Fractions were collected
and stored at –80uC until use for in vitro kinase assays. Purity was
analysed by SDS-PAGE (10%) and visualization using GelCode
Blue Stain Reagent (Pierce Biotechnology, Rockford IL USA)
following the manufacturer’s instructions.
In vitro Kinase Assay
U1A cells [4] were transiently transfected with expression
vectors pEGFP (Clontech Laboratories, Inc., Palo Alto CA USA),
pEFmTyk2 or pEFmTyk2
K923E, applying the Superfect transfec-
tion technique (Qiagen, Hilden Germany). The in vitro kinase assay
was performed as described previously [19,22]. 18 hours post
transfection cells were harvested and whole cell extracts prepared.
500 mg whole cell extracts were incubated with 4 mg anti-TYK2
antibody per sample with slow rotation at 4uC for 4 hours. 50 ml
protein A slurry (50%; GE Healthcare, Little Chalfont UK) were
added and incubated with slow rotation at 4uC for 2 hours.
Immunoprecipitates were washed twice with 1 x lysis buffer and
once with kinase buffer (50 mM NaCl, 5 mM MgCl2,5 m M
MnCl2, 0.2 mM NaVanadate, 10 mM HEPES pH 7.4). Pellets
were resuspended in 50 ml kinase buffer supplemented with c-
32P-
ATP (10 mCi per reaction; redivueTM adenosine 5‘-[c-
32P]
triphosphate, triethylammonium salt; GE Healthcare, Little
Chalfont UK). For assays of in vitro kinase activity on an exogenous
substrate, the kinase reaction mixture was further supplemented
with GST-IFNAR2cyt (1 mg/reaction). Kinase reactions were
performed on a thermo-mixer (Eppendorf, Germany) shaking
the tubes vigorously (1500 rpm) at 30uC for 5 minutes. Enzymatic
activity was terminated by adding 75 ml2 6LSB. Samples were
analysed by SDS-PAGE (7%) and autoradiography.
Mice and Genotyping
C57BL/6N (WT) mice were purchased from Charles River
Laboratories. Tyk2
2/2 (B6N.129P2-Tyk2
tm1Biat) mice have been
previously described [6] and were on C57BL/6N background.
Tyk2
K923E (B6;129P2-Tyk2
tm3(K923E)Biat or B6N.129P2-Tyk2
tm3(-
K923E)Biat) animals were on either mixed or C57BL/6N
background. Data shown in Figs. 1–3 were from mixed
background and data in Figs. 4 and 5 from pure bred mice.
Experiments were performed with sex- and age-matched (8 to 12
week old) mice. Southern blot analysis was performed as
described [32]. Tyk2
K923E mice were screened by detection of
the BspTI fragment using the primers 68.BspTIf 59-CGA-
GATGGCTCAGCGGATAA-39 and 89.K-E.rev 59-
TGGTCAGGCCAGGATAGTTC-39 or by an assay designed
to detect the loxP site (82.K-E.rev 59-TGCACTGCGATTCC-
TAACAG-39, 83.K-E.fwd 59-CCAGGATCCAGAGACTCCAA-
39).
Cell Culture
Bone marrow-derived macrophages (BMMWs) were isolated
and grown in the presence of CSF-1 derived from L929 cells as
described previously [42]. Cells were cultivated in DMEM (PAA
Laboratories, Pasching Austria) containing 10% heat-inactivated
fetal bovine serum (FCS; Invitrogen Europe), 1 mM L-glutamine,
100 U/ml penicillin and 100 mg/ml streptomycin (Pen/Strep;
Invitrogen Europe), 50 mM b-mercaptoethanol (b-ME; Invitrogen
Europe) and 15% L929 cell-conditioned medium. Cells were
cultivated for 8 days before the experiments. For isolation and
culture of aCD3e-activated T cells, spleens were removed,
homogenized through a 100 mm cell strainer (BD Falcon
TM,B D
Biosciences Europe, Erembodegem Belgium) and incubated with
Figure 3. IFN treatment leads to similar activation of JAKs and STATs in Tyk2
K923E and Tyk2-deficient cells. BMMWs were treated with
IFNb (500 U/ml) for 20 min or left untreated. Whole cell extracts were used to determine levels of JAK1 tyrosine phosphorylation and JAK1 expression
(left panel) and of TYK2 tyrosine phosphorylation and TYK2 expression (right panel) by immunoprecipitation and Western blot analysis. B.-D. BMMWs
were treated with IFNa (500 U/ml), IFNb (100 U/ml) or IFNc (100 U/ml) for 20 min or left untreated. Whole cell extracts were used to determine
STAT1a/b tyrosine phosphorylation and levels of STAT1a/b expression (B), levels of STAT2 tyrosine phosphorylation and STAT2 expression (C) and
levels of STAT3 tyrosine phosphorylation and STAT3 expression (D) by Western blot analysis. E. BMMWs were treated with IFNb (10, 100 or 500 U/ml)
for 20 min or left untreated and Western blot analysis performed as described in (B). F. NK cells were treated with the indicated doses of IFNb for
20 min or left untreated. Levels of tyrosine phosphorylation and protein expression of STAT1a/b and STAT4 were analysed by Western blot. G. NK
cells were treated with IFNa (500 U/ml) for the times indicated and STAT1 and 4 analysed as described in (F); H. NK cells were treated with IFNb
(100 U/ml) for the times indicated and STAT1 and 4 analysed as described in (F); ERK p85 (B, C, E-H) and ERK p42 (D) served as a loading control.
doi:10.1371/journal.pone.0039141.g003
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to the manufacturer’s instructions. T cells were activated with
aCD3e-Ab (0.5 mg/ml; BD Pharmingen, BD Europe) and cultured
for 3 days in RPMI 1640 (Invitrogen Europe) containing L-
glutamine (PAA Laboratories, Pasching Austria) supplemented
with 10% FCS, Pen/Strep (100 U/ml, 100 mg/ml), 50 mM b-ME,
16non-essential amino acids (NAA; PAA Laboratories, Pasching
Austria), 1 mM sodium pyruvate (Gibco, Invitrogen Europe) and
100 U/ml recombinant human IL-2 (rhIL-2, Proleukin, Novartis
Austria). For NK/NKT cell culture, freshly isolated splenocytes
were incubated with MACS DX5-coupled beads (Miltenyi Biotec,
Bergisch Gladbach Germany) and subjected to positive selection
using the appropriate column system. Subsequently, cells were
cultured in RPMI 1640 containing L-glutamine supplemented
with 10% FCS, Pen/Strep (100 U/ml, 100 mg/ml), 50 mM b-ME
and 5000 U/ml rhIL-2 for 10 days.
Cytokines and Inhibitors
Recombinant mouse IFNa (IFNaA = IFNa3), IFNb and IFNc
were from CalbiochemH (Merck4Biosciences, Darmstadt Ger-
many). Inhibitors: Z-Leu-Leu-Leu-aI (MG-132; Sigma Aldrich
Austria), 3-methyladenine (3-MA; Sigma Aldrich Austria), bafilo-
mycin A1 (Sigma Aldrich Austria) and JAK inhibitor I (panJak
inhibitor; CalbiochemH, Merck4Biosciences, Darmstadt Ger-
many).
Isolation of Total RNA, Reverse Transcription and
Quantitative PCR
Cells were lysed and organs homogenized in peqGOLD TriFast
(PEQLAB, Erlangen Germany), RNA was isolated according to
the manufacturer’s instructions. RNA purity was determined by
spectrophotometry and agarose gel electrophoresis. 1 mg of RNA
was reverse transcribed using the iSCRIPT cDNA synthesis kit
(BIO-RAD Austria). Quantitative PCR was performed on an
Eppendorf realplex4 or a Stratagene MX3000.
The primer and probes for Ube2D2 have been described
previously [42]. QuantiTectH Primer Assays (Qiagen, Hilden
Germany) were reconstituted according to manufacturers instruc-
tions. The following assays were used: Mm_Socs_1_SG, Mm_I-
fi204_2_SG, Mm_Tap1_1_SG, Mm_Oas1a_1_SG, Mm_I-
fit1_1_2 and Mm_Irgm1_1_SG. Hot FIREPolH DNA
Polymerase (Solis Biodyne, Tartu Estonia), EvaGreenH (Biotium
Inc, Hayward CA USA) and dNTP Set (Fermentas Thermo-
Scientific Austria) were used according to manufacturers instruc-
tions. The following additional primers were used: Tyk2-fwd: 59-
TGACAGGTGTCCCTGTGAGATCTAT-39, Tyk2-rev: 59-
CTGGAGGATGGGCACAAGA-39, Tyk2 probe: 59-
TCCTTCCGGCCCACCTTCCAGA-39 (FAM); Irf7-fwd: 59-
TCTTCCGAGAACTGGAGGAGTT-39, Irf7-rev: 59-
TCTCCTTGGGCCTCCCTG-39, Irf7 probe: 59-
CTCGGAGGCGGCAAGGGTCA-39 (FAM/BHQ1).
RT-qPCR data were analysed using realplex (Eppendorf,
Vienna Austria) software and the standard curve method used
for the calculation of relative expression levels as previously
described [42,43,62]. Statistical analysis was undertaken with the
software SPSS 17.0 (Mac OS-X). Data were log-transformed for
approximate normality and analysed with a linear model
(ANOVA) with genotype, treatment and interaction as factors.
Appropriate contrasts were calculated (with SPSS) and resulting p-
values are reported.
Whole Cell Extracts (WCE), Immunoprecipitation (IP) and
Western Blot Analysis (WB)
Cells were lysed in 50 mM Tris/HCl pH 8.0, 10% (v/v)
glycerol, 25 mM EDTA, 150 mM NaCl (all from ROTH,
Karlsruhe Germany), 2 mM DTT, 0.5% NP40 (Igepal CA-630),
25 mM sodium fluoride, 1 mM sodium vanadate, 0.5 mM PMSF,
SIGMAFAST Protease Inhibitor (all from Sigma Aldrich Austria)
and cell debris removed by centrifugation. For IPs, 1 or 3 mg
protein/ml from freshly prepared whole cell extracts (WCE) were
incubated with 2 mg/ml antibody at 4uC overnight. 50 ml Protein
A SepharoseH CL-4B (50% v/v; GE Healthcare, Little Chalfont
UK) was added and samples incubated with slow rotation at 4uC
Figure 4. Transcriptional induction of IFN-responsive genes is similar in Tyk2
K923E and Tyk2
2/2 cells. A.-C. WT, Tyk2
2/2 and Tyk2
K923E
BMMWs were treated with IFNa (500 U/ml), IFNb (100 U/ml) or IFNc (100 U/ml) for 6 h or left untreated. Total RNA was extracted, reverse-transcribed
and analysed by RT-qPCR for expression of Oas1a, Ifit1 (A), Cxcl1, Socs1 (B) and Irf7, Tap1 (C). Ube2D2 was used for normalization and expression levels
were calculated relative to untreated WT cells. Data are derived from three independent experiments and depicted as mean values (+/2 SE). D. WT,
Tyk2
2/2 and Tyk2
K923E BMMWs were treated with indicated doses of IFNb for 6 h. Target gene expression was determined as described in A-C. Mean
values (+/2 SD) derived from two independent experiments are depicted. Note that due to sample size a statistical analysis was not performed.
doi:10.1371/journal.pone.0039141.g004
Figure 5. Tyk2
2/2 and Tyk2
K923E mice show similarly increased
susceptibility to virus infection. VSV (A) was administered
intranasally (i.n.) and EMCV (B) intraperitoneally (i.p.). Mice were
monitored twice daily for survival over a two-week period. Data are
derived from two independent experiments (n=20/genotype and
n=21/genotype for A and B, respectively).
doi:10.1371/journal.pone.0039141.g005
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resuspended in 50 ml2 6Laemmli sample buffer. Proteins were
separated with SDS-PAGE and blotted onto nitrocellulose
membranes (Hybond, GE Healthcare, Little Chalfont, UK). For
IPs, the amount loaded per lane corresponds to 400 mg input cell
lysate (derived from 1610
6–2610
6 cells). For WBs, 15 mg total cell
lysate was loaded per lane (derived from 4610
428610
4 cells).
PageRulerH Prestained Protein Ladder (Fermentas ThermoScien-
tific Austria) was used as molecular weight standard. Membranes
were probed with the indicated antibodies and the ECL Western
blotting detection system (GE Healthcare, Little Chalfont, UK).
Antibodies: anti-phospho-Stat1 (Tyr701), anti-Stat1, anti-phos-
pho-Stat3 (Tyr705), anti-Stat3, anti-Stat4 (C46B10) and anti-
phospho-tyrosine (Y1054/1055) Tyk2 (human) were from Cell
Signaling Technology (New England Biolabs GmbH, Frankfurt
Germany), anti-panERK (p42/p44 (ERK1/2) and 56 kDa and
85 kDa family members) and anti-phospho-Stat4 (Tyr693) from
BD Transduction Laboratories (BD Biosciences Europe, Erembo-
degem Belgium), anti-NFkB (p65, CT), anti-phospho-Stat2
(Tyr689) and anti-Stat2 from UpstateH (Millipore, Billerica MA
USA) anti-phospho-tyrosine (PY20), anti-heme oxygenase-1 (HO-
1), anti-Jak1 (HR-785) and anti-Jak2 (C-20) from Santa Cruz
BiotechnologyH (Santa Cruz CA USA), anti-LC3 from Sigma
Aldrich (Austria). TYK2 antibody (rabbit polyclonal) was raised
against an N-terminal peptide of murine TYK2. Peroxidase-
conjugated secondary antibodies (mouse and rabbit) were from
GE Healthcare (Little Chalfont UK).
Virus Infection
Vesicular stomatitis virus (VSV), Indiana strain was provided by
T. Decker (MFPL, University of Vienna, Austria) and Encephalo-
myocarditis virus (EMCV) was from A. Pichlmair (CeMM, Austrian
Academy of Sciences, Vienna Austria). Age- and sex-matched
mice were infected intraperitonally (i.p.) with 50 plaque forming
units (pfu) EMCV. For VSV challenges, age-matched female mice
were anaesthetized by intraperitonal injection of ketamine-
xylazine (100 mg ketamine/kg body weight and 4 mg xylazine/
kg body weight; Ketasol and Xylasol, Graeub AG, Switzerland)
and infected intranasally (i.n.) with 10
5 pfu in 20 ml of phosphate-
buffered saline (10 ml/nostril).
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